Evoke Pharma, Inc.

The company, Evoke Pharma, focuses on developing and commercializing drugs for gastroenterological disorders. It offers Gimoti, a metoclopramide nasal spray for diabetic gastroparesis symptoms. Products are marketed to gastroenterologists, internal medicine specialists, primary care physicians, and select healthcare providers. The company was incorporated in 2007. Headquartered in Solana Beach, California.

Overview

Sector

Pharmaceutical

Target Price

0.0 USD

Current Price

11.0 USD

Potential

-100%

Strengths

Price to book ratio (2.32) is lower than the sector mean (733.70).

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (14.71%).
EV/EBITDA (100.00) is significantly higher than the sector mean (51.86).
The Price to Free Cash Flow ratio (100.00) is significantly higher than the sector mean.
EBITDA Margin (0.00%) appears relatively low.

Indicator	Value
PER	100.0
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	1.7

Evoke Pharma, Inc.

Overview

Strengths

Weaknesses

Key Financial Data